Reyes, A., Révil, C., Niggli, M., Chebon, S., Schlagmüller, S., Flacke, J., Zortel, M., Paz-Priel, I., Asikanius, E., Hampton, R., Mahajan, A., Schmidt, E., & Edwards, S. C. (2020). reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079–2087. Current medical research and opinion, 36, 1129–1130. http://access.bl.uk/ark:/81055/vdc_100105441817.0x00004b